Runben Biotechnology (SH:603193) Western Securities·2025-08-29 06:41Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company achieved a revenue of 895 million yuan in the first half of 2025, representing a year-on-year increase of 20.31%, with a net profit attributable to shareholders of 188 million yuan, up 4.16% year-on-year [1][4] - The strong performance in the infant and child care segment is driving growth, with significant contributions from the egg yolk oil special care series and children's sunscreen products [1] - The company is strategically expanding its product matrix to include youth-oriented products, which is expected to enhance user lifetime value and open a second growth curve [3] Summary by Sections Financial Performance - In Q2 2025, the company reported a revenue of 655 million yuan, a year-on-year increase of 13.46%, while the net profit was 143 million yuan, down 0.85% year-on-year [1][4] - The infant care revenue reached 405 million yuan, up 38.73% year-on-year, while the mosquito repellent product growth slowed to 13.43%, totaling 375 million yuan [1][2] - The overall gross margin for H1 2025 was 58.01%, a slight decrease of 0.63 percentage points year-on-year, with a net profit margin of 20.95%, down 3.25 percentage points year-on-year [2] Product and Market Strategy - The company is launching over 40 new products, including a youth acne treatment series and children's sunscreen gel, which are expected to drive revenue growth in the second half of the year [3] - The company is deepening its channel layout, with significant online and offline sales growth, including new partnerships with major retailers [1][2] Future Projections - The company forecasts revenue growth rates of 20.7% for 2023, 27.6% for 2024, and 23.6% for 2025, with net profit growth rates of 41.2%, 32.8%, and 10.2% respectively [3][8] - Expected EPS for 2025 is projected at 0.82 yuan, with a P/E ratio of 37.0 [3][8]